Tivantinib Provides No Survival Benefit in Hepatocellular Carcinoma Patients, Phase 3 Study Shows
Liver cancer, News
Tivantinib, an experimental oral inhibitor of the MET receptor, is not better than best supportive care in patients with inoperable hepatocellular carcinoma (HCC) who are intolerant or have previously received systemic therapy. ... Read more